EXcretion and distribution of iron during chronic deferoxamine therapy.
D000741:Anemia, Aplastic / Q000628:therapy; D001853:Bone Marrow / Q000032:analysis; D001856:Bone Marrow Examination; D002648:Child; D002859:Chromium Isotopes; D003676:Deferoxamine / Q000627:therapeutic use*; D005492:Folic Acid / Q000627:therapeutic use; D006333:Heart Failure / Q000209:etiology; D006486:Hemosiderosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007501:Iron / Q000032:analysis / Q000378:metabolism* / Q000652:urine; D007502:Iron Chelating Agents / Q000378:metabolism; D008099:Liver / Q000032:analysis; D008297:Male; D012157:Mononuclear Phagocyte System / Q000378:metabolism; D010110:Oxymetholone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011736:Pyridoxine / Q000627:therapeutic use; D013154:Spleen / Q000032:analysis; D013156:Splenectomy; D014020:Tissue Extracts; D065227:Transfusion Reaction; D014805:Vitamin B 12 / Q000627:therapeutic use
D002859:Chromium Isotopes; D007502:Iron Chelating Agents; D014020:Tissue Extracts; D005492:Folic Acid; D007501:Iron; D003676:Deferoxamine; D011736:Pyridoxine; D010110:Oxymetholone; D014805:Vitamin B 12; D011241:Prednisone